Zenotech laboratories Limited has issued a clarification to BSE Limited regarding recent significant movement in its stock price, confirming that the company remains in full compliance with regulatory disclosure requirements and has not withheld any material information.

BSE Query and Company Response

The clarification came in response to BSE's email dated April 09, 2026, which noted significant price movement in Zenotech Laboratories' stock and requested the company to provide any information or announcements that might explain the price behavior under Regulation 30 of SEBI (LODR) Regulations, 2015.

Compliance Confirmation

In its formal response, Zenotech Laboratories emphasized its consistent adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company explicitly confirmed compliance with Regulation 30 requirements, which mandates disclosure of material events and information that could impact stock price behavior.

The company stated that it has not withheld any material information or events that, in its opinion, would have a bearing on the price behavior of its stock. This confirmation addresses BSE's specific query about potential undisclosed developments that might explain the recent price movement.

Corporate Details

The clarification was signed by Abdul Gafoor Mohammad, Company Secretary & Compliance Officer, who holds ICSI Membership No. A22331. The response was digitally signed and submitted to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai.

Company Information

Zenotech Laboratories Limited operates from its registered office and factory located at Survey No. 250-252, Turkapally Village, Genome Valley Road, Shamirpet Mandal, Medchal-Malkajgiri District, Hyderabad. The company maintains its commitment to regulatory compliance and transparent communication with stock exchanges and investors.

Zenotech Laboratories Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation for the quarter ended March 31, 2026, demonstrating adherence to securities dematerialization protocols.

Regulatory Compliance Filing

The compliance certificate was submitted on April 07, 2026, pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. The certificate, dated April 06, 2026, was issued by KFin Technologies Limited, which serves as the company's Registrar & Share Transfer Agent.

Certificate Confirmation

KFin Technologies Limited confirmed that all securities received from depository participants for dematerialization during the quarter ended March 31, 2026 were properly processed. The registrar verified that:

• Securities received for dematerialization were confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within 15 days

Company Leadership

The compliance certificate was signed by Abdul Gafoor Mohammad, Company Secretary & Compliance Officer of Zenotech Laboratories Limited. Mohammad holds ICSI Membership No. A22331 and digitally signed the document on April 07, 2026.

Corporate Information

Zenotech Laboratories Limited operates from its registered office and factory located at Survey No. 250-252, Turkapally Village, Genome Valley Road, Shamirpet Mandal, Medchal-Malkajgiri District, Hyderabad. The company maintains its corporate identification number as L27100TG1989PLC010122, reflecting its incorporation in Telangana in 1989.

The quarterly compliance filing represents standard regulatory practice, ensuring transparency in securities handling and maintaining investor confidence through proper documentation of dematerialization processes.